Stem-cell-derived islets for type 1 diabetes: why this research matters.

Type 1 diabetes is not a wellness problem and it is not an inflammation problem. The body’s own immune system attacks and destroys the cells in the pancreas that make insulin. The future-facing question is precise: can researchers manufacture insulin-making cells in a lab, place them safely in the body, and have them respond to blood sugar the way the original cells did before the disease took them?¹

This is one of the clearest stories in regenerative medicine right now. It is also one of the most often borrowed, without credit, by clinics selling something different. The point of this page is to keep those two things apart: the science of stem-cell-derived islet cells on one side, and the generic “stem cells for diabetes” claim on the other.

This page sits underneath where stem cell research is heading, the parent map of cell-replacement directions in regenerative medicine. Islet cells are one of the most defined branches of that map.

What an islet cell actually is.

The pancreas is two organs in one. Most of it makes the enzymes that help digest food. A small fraction of it is made up of tiny clusters of hormone-producing cells called pancreatic islets — sometimes called islets of Langerhans, after the German anatomist who first described them.

Inside each islet, several cell types live side by side. The ones that matter most for diabetes are the beta cells. Beta cells are the body’s built-in blood-sugar sensors: when glucose rises after a meal, they release insulin; when glucose falls, they ease back. That moment-to-moment loop is what keeps blood sugar inside the narrow band the rest of the body needs.

In type 1 diabetes, the immune system destroys those beta cells. Insulin therapy replaces the hormone they were making, which is life-saving and miraculous — but it does not replace the living, glucose-sensing cell. It is a tool a person uses to do, by hand and pump, what the missing cell used to do automatically.

Islet transplantation, where donor islets from a deceased donor’s pancreas are infused into a recipient’s liver, already exists in specialized medicine. In the United States, the first cellular therapy of this kind — donislecel — received FDA approval in 2023 for a narrow group of adults with severe hypoglycemia unresponsive to intensive management.² It is a real, scoped option for a small population. It is also limited by something the body cannot solve: donor pancreases are scarce, and every recipient ties up a supply that cannot be scaled.

Why stem-cell-derived islets are a different idea.

Stem-cell-derived islets start from a different place. Researchers begin with pluripotent stem cells — cells capable of becoming almost any cell type in the body — and walk them through a sequence of lab steps designed to mimic early pancreas development, until they behave like real islet cells that secrete insulin in response to glucose.

The point is not to invent a new cell type. The point is to make the cell type the disease destroyed, from a source that does not depend on a donated pancreas. Done well, this turns a scarce, one-recipient-per-donor resource into a manufactured product that can in principle be made, tested, and released to many patients from the same starting line.

The honest framing is that the field is moving from cells as hope toward cells as a defined product. A defined product is one that has a named cell source, a named manufacturing process, a named dose, a named delivery route, a named indication, and a named regulator looking at it. Two therapies described as “islet cells” can be wildly different on every one of those lines. “Same cell type” is not the same as “same product.”

What early human trials are trying to show.

A short tour of the work happening now — what the most visible program has reported, what the pivotal trial is asking next, and how other labs around the world are testing the same idea in different ways.

What remains unknown.

“Unknown” is not the same as “failed.” These are the questions clinical translation exists to answer, and the fact that they are open is the reason the work has not been declared finished.

• Durability. Most published results live somewhere between months and a year or two. How well a graft still works at five, ten, or twenty years out is the question the long-term registries are built to answer, and the data are not in yet.
• Who is a candidate. The current trials enroll people whose type 1 diabetes is complicated by severe hypoglycemia or impaired awareness — a defined, high-risk group. Whether the same approach is appropriate for people with more typical type 1 diabetes is a separate question, and one the early studies are not designed to answer.
• Immune rejection and autoimmunity.The same disease that destroyed the original beta cells can attack new ones, and the immune system can also reject any foreign cell. Most current trials handle both with chronic immunosuppression. Programs testing device-encapsulation or gene-edited “hypoimmune” cells are trying to reduce or remove that requirement, but the data on those approaches are still early.
• Side effects of the immune-protection strategy. Chronic immunosuppression itself carries real risks — infections, kidney effects, blood-count effects. A therapy that frees a person from insulin but trades it for a different long-term risk profile is a real medical decision, not a brochure decision.
• Manufacturing consistency. A cell product is only as good as the batch in the vial. Making the same product the same way, batch after batch, at the scale a real disease needs, is one of the hardest unsolved problems in the field.
• Cost and access. Even if everything works, cell therapies are expensive to manufacture, deliver, and follow up on. Who can actually get one, and through which health system, is a separate set of decisions on top of the science.
• Scale beyond trial centers. Today, this kind of work happens at a handful of specialized academic centers. How — and whether — it can move out of that setting is part of what the next several years are trying to figure out.

Why this does not validate “stem cells for diabetes” clinic claims.

This is the part that matters most for any reader who has seen a clinic ad. A registered, peer-reviewed trial of stem-cell-derived islets is not the same as a clinic-room IV labeled “stem cell therapy for diabetes.” The differences are not cosmetic.

• Different cell. A stem-cell-derived islet product is a specific kind of pancreatic islet cell, made on purpose. A wellness IV is usually generic mesenchymal stromal cells, exosomes, or undefined material. They are different biological things.
• Different process. The trial product is made under a documented manufacturing process with release testing and named potency assays. The clinic version, in many cases, has none of that.
• Different delivery. Current trials deliver cells into the hepatic portal vein under image guidance, or into specific sites under defined protocols. An IV bag in an exam room is not the same delivery.
• Different patient group. Trial participants are selected by strict criteria; clinic ads are usually written for broad demand, not narrow eligibility.
• Different oversight. A registered trial is listed on a public registry, has a protocol, has an ethics board, and has a regulator reading along. A clinic claim has, at most, a website.

If a clinic references islet-cell research, ask whether it is offering the same cell, the same process, the same delivery, the same patient group, and the same oversight. If the answer is no on any of those, the clinic is not offering the research it is quoting. The product field guide to PRP, BMAC, MSCs, and exosomes is a useful sibling read on this point — different products, different evidence, often the same marketing language.

Where this research is being done.

A short, intentionally non-directory orientation. None of these are an endorsement; each is a place where the public record can be read.

• Vertex Pharmaceuticals. Company sponsor of the zimislecel program (previously VX-880). The clinical program is being run at academic transplant centers in several countries. We read company context for what it is — context — and ground the science in the peer-reviewed publication and the trial record, not in press releases.¹⁰
• Academic islet biology and transplantation centers. A small number of academic groups — in the United States, Canada, the EU, the UK, and Japan — anchor most stem-cell-derived islet work, often in collaboration with industry sponsors. They are where decades of donor-islet transplantation expertise and modern stem-cell biology meet.
• ClinicalTrials.gov, jRCT, and other registries. The patient-readable layer of all of the above. Any “international protocol” claim for a stem-cell-derived islet therapy should be findable in a public trial registry. If it is not, that is itself a useful piece of information.
• The broader cell-therapy ecosystem. Diabetes cell therapy sits inside a wider regenerative-medicine landscape — Parkinson’s cell replacement, retinal cell therapies, engineered immune cells. The same standards of defined product, defined indication, and defined oversight apply across all of them, and progress in one branch does not automatically transfer to another.

How to read the next headline.

The next time a diabetes-and-stem-cells story crosses your feed, a short checklist is enough to put it in the right column.

• What kind of cells? Donor islet transplant, stem-cell-derived islets, mesenchymal-stem-cell infusion, or something else? These are different things.
• In humans? A result in mice or in a dish is not a result in a patient.
• Registered trial? Phase, sponsor, registry number, and country should be on the record.
• Insulin production measured?Was the cell actually making insulin in response to glucose, not just “present”?
• Immune suppression required? A therapy that avoids it is a different therapy from one that needs it for life.
• How long is the follow-up? A year is not the same as a decade, and durability is the open question.
• Who manufactured the product? An academic group, a company, or a clinic each carries a different signal.
• Available care or a trial? These are different answers to the same question, and clinics often blur them.

The general version of this checklist for any stem-cell headline lives in questions to ask any stem-cell clinic; the specific shape of clinic marketing patterns to recognize lives in stem-cell clinic red flags.

What this means today.

Stem-cell-derived islet cells are one of the cleanest examples of regenerative medicine becoming specific. The cell type the disease destroys is known. The cell type the lab can now make is known. The bridge between them is real, public, and being measured. That is rare in this field, and it is part of why this story keeps being told.

None of this is routine care for most people with type 1 diabetes today. It lives inside specialized clinical trials, in defined patient groups, under chronic immunosuppression for now, with the pivotal data still being collected. Following this work is reasonable. Acting as if it has already arrived is not.

The healthier posture is curious patience: read the trial record, read the registry, read the peer-reviewed paper, and keep the brochure in its own bucket. A page like stem cells in autoimmune disease, in plain English is a useful sibling read, because type 1 diabetes is also autoimmune at heart and many of the same considerations recur.

Hope is the right response to this work. So is precision.

Trust and contexthow to read stem cell evidence without getting lost · methodology · sources · disclosures

Frequently asked.

Can stem cells cure type 1 diabetes?

Not today. The most defined direction — stem-cell-derived islet cells — has produced promising early results in a small Phase 1/2 trial published in 2025, but the therapy still requires chronic immunosuppression and was tested in a narrow patient group. Promising and real, not a cure rolled out to everyone.

Are stem-cell-derived islets the same as islet transplantation?

They are cousins, not the same thing. Donor-islet transplantation uses cells from a deceased donor’s pancreas; stem-cell-derived islets are grown in a lab from a pluripotent starting cell. Both deliver insulin-producing cells, but the source, the supply, and the long-term picture are different.

Do stem-cell-derived islet cells make insulin?

In the published zimislecel trial, yes — the lab-grown cells engrafted in the liver and produced insulin in response to blood sugar in adults with type 1 diabetes complicated by severe hypoglycemia. Whether the same result holds in a larger pivotal trial, over longer follow-up, in broader patient groups, is exactly the question the field is now trying to answer.

Is this available outside clinical trials?

No. Stem-cell-derived islet cells live inside registered clinical trials at a small number of academic centers, with strict eligibility criteria. Any clinic claiming to offer this product or the same thing is offering something the trial record does not support.

How is this different from stem-cell clinics advertising diabetes treatment?

A stem-cell-derived islet trial is a specific cell product, delivered into a specific place, in a specific patient group, under regulator oversight. A wellness IV of generic mesenchymal stem cells is a different cell type, made a different way, for a different question, with no comparable evidence. A result in one does not validate the other.